Skip to main content

Table 2 Influence of treatment with GAT107 on the clinical parameters of EAE

From: Suppression of neuroinflammation by an allosteric agonist and positive allosteric modulator of the α7 nicotinic acetylcholine receptor GAT107

  Mean severity Cumulative score Max score Day of onset
Placebo 1.8 ± 0.15 33.8 ± 2.9 2.25 ± 0.14 11.2 ± 0.5
GAT107 0.4 ± 0.12** 8.1 ± 2.4** 0.68 ± 0.18** 14.2 ± 0.6*
  1. *p < 0.05, **p < 0.001